Clinical trials
Lupus or SLE clinical trials
Below are recruiting lupus or sle clinical trials, each written for real people, not researchers. We’re tracking 333 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07053800RecruitingPhase 2
Obe-cel for severe lupus with kidney inflammation
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
New York, New YorkAges 12–65 - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT06585514RecruitingPhase 1/Phase 2
CAR T-cell therapy for hard-to-treat lupus
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
Beijing, Beijing MunicipalityAges 3–65 - NCT06121297RecruitingPhase 1/Phase 2
CABA-201 treatment for systemic lupus erythematosus
This study tests a new treatment called CABA-201 for people with active systemic lupus erythematosus (SLE). The treatment aims to reduce disease activity and may help those who haven't responded well to other treatments.
Orange, CaliforniaAges 12–65 - NCT04702256RecruitingPhase 3
Treating lupus kidney inflammation with or without extra steroid tablets
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
ParisAges 14 years+ - NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Anniston, AlabamaAges 18–75 - NCT04604990Recruiting
National lupus patient study for adults in Saudi Arabia
This study follows adults with systemic lupus erythematosus (lupus) to better understand the condition over time. If you meet common lupus diagnosis standards, you may be able to join—there’s no limit on when you were diagnosed.
Riyadh, Central ProvinceAges 19 years+ - NCT06167174Recruiting
Looking for markers to predict lupus kidney treatment response
This study is looking for biomarkers (clues in your blood, urine, or tissue) that can help predict how well lupus nephritis (kidney inflammation caused by lupus) responds to treatment. It focuses on people who have active kidney disease and are either starting treatment or have been on a stable treatment for at least a month.
BeijingAges 16–60 - NCT07855302RecruitingPhase 1
CAR T-cell therapy for young people with lupus
This trial tests a treatment that uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. It is for young people whose lupus is active despite trying several standard treatments.
SeoulAges Up to 25 years - NCT07829614RecruitingPhase 1
F182112 study for people with lupus
This study tests a new drug called F182112 for people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. The drug targets certain immune cells to possibly reduce lupus symptoms.
ShanghaiAges 18–65 - NCT07720310Enrolling by invitation
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Lyasny, Minsk OblastAges 18–70 - NCT07713940Recruiting
Anti-inflammatory diet study for lupus patients
This study tests whether an anti-inflammatory diet can help people with lupus who are on certain medications. It focuses on reducing pain and improving quality of life over 12 weeks.
La Jolla, CaliforniaAges 18 years+ - NCT07679776Enrolling by invitation
Study on early vision changes in lupus patients
This study looks at whether people with systemic lupus erythematosus (SLE) have early signs of vision problems. Eye tests will be used to check how well you see and if there are any hidden issues in your eyes.
Hefei, AnhuiAges Any age - NCT07657793RecruitingPhase 2/Phase 3
Sirolimus for Lupus-Related Low Platelets
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
Beijing, Beijing MunicipalityAges 18–65 - NCT07617740RecruitingEarly Phase 1
IASO207 cell therapy for treatment-resistant lupus
This early-stage trial tests IASO207, a new cell therapy designed to help people with severe lupus that hasn't improved with standard medications. The therapy works by modifying immune cells to reduce lupus activity.
BeijingAges 18–75 - NCT07564596RecruitingPhase 1/Phase 2
A Study of Budoprutug for Systemic Lupus Erythematosus
This trial tests budoprutug, an experimental drug, to see if it helps people with systemic lupus erythematosus (SLE) whose disease is not well controlled by current treatments. The drug targets immune cells that may be driving the disease.
Mianyang, SichuanAges 18–65 - NCT07490041RecruitingEarly Phase 1
CAR-NK cell therapy for refractory childhood rheumatic diseases
This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.
Hangzhou, ZhejiangAges 5 years+ - NCT07483346RecruitingPhase 1
Testing IASO-782 for systemic lupus erythematosus
This trial tests a new medicine called IASO-782 for people with systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms when added to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07447986RecruitingPhase 2
Testing a New Injection for Lupus (SLE)
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT07444307RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.
Hefei, AnhuiAges 18–65 - NCT07425730Recruiting
Heart problems in childhood lupus study
This study looks at early heart function problems in children with lupus to find those at risk for severe disease. It may help doctors identify and treat severe lupus sooner.
Shanghai, Shanghai MunicipalityAges 7–17 - NCT07409181RecruitingPhase 2
Testing an experimental pill for active lupus (SLE)
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
Beverly Hills, CaliforniaAges 18–74 - NCT07339332RecruitingEarly Phase 1
CAR-T cell therapy for moderate to severe lupus
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
Wuhan, HubeiAges 18–65 - NCT07311200RecruitingPhase 2
Study of D-2570 for active lupus
This trial tests a new oral medication called D-2570 for people with active systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms while you continue your current stable treatments.
Linfen, JiangxiAges 18–70
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus or sle?
- Yes. Clin2 currently lists 333 recruiting lupus or sle studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus or sle trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus or sle trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.